Investing in Platforms

1. High Content Clinical Trials
This will include development and maintenance of a world-class tumour bank overseen by Dr. Sylvia Asa and Dr. Patricia Shaw which will allow many of our scientists to collect, store and learn from tumour samples – a tremendously valuable and significant advantage for researchers at PMH.

2. Drug Development Program
Dr. Malcolm Moore, Director of the Robert and Maggie Bras and Family New Drug Development Program leads this program. This is a top-tier drug testing facility that is the only non-U.S. site to receive both a phase I grant and a phase II contract from the U.S. National Cancer Institute.  It means that Princess Margaret Hospital is able to offer the most promising treatment options to its patients.

3. New Targets and Combinations
Dr. Ben Neel will lead work on RNAi/Drug and RNAi platforms which will ultimately help identify potential genetic mutations and targets for new drugs.

Drs. Robert Rotapel, Thomas Kisslinger and Brian Raught and others will lead work in biomarkers, which is the study of biochemical features that can be used to measure the progress of disease or the effects of treatment.

Dr. Igor Jurisica, a world leader in the field of bioinformatics and system biology, will lead this area which includes computational biology which gathers and translates large amounts of data into useful formats and also creates new models for interpreting and understanding information as it relates to cancer research.
You have an old version of Adobe's Flash Player. Get the latest Flash player.